CLAIMS

1. A pharmaceutical composition comprising:

(a) a therapeutically effective amount of at least one compound selected from the group consisting of:

(*R**)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone;

5-{[2-Fluoro-3-(trifluoromethyl)phenyl]carbonyl}-1-pyrazin-2-yl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine;

(S*)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone;

(*R**)-(2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(1H-pyrazol-5-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone;

(6S)-1-(5-Fluoropyrimidin-2-yl)-5-{[2-fluoro-3-(trifluoromethyl)phenyl]carbonyl}-6-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine; and

(6R*)-5-[(2,3-Dichloro-4-fluorophenyl)carbonyl]-1-(5-fluoropyrimidin-2-yl)-6-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine; and

(b) at least one pharmaceutically acceptable excipient,

wherein the composition is formulated for oral administration.

2. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for the treatment of a condition selected from the group consisting of: major depressive disorder, treatment-resistant depression, anxious depression, bipolar disorder, anxiety, epileptic seizures, Alzheimer’s disease, Parkinson’s disease, irritable bowel syndrome, Crohn’s disease, rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, allergic asthma, allergic rhinitis, neuropathic pain, inflammatory pain, and spontaneous pain.

3. The use according to claim 2, wherein the condition is selected from the group consisting of irritable bowel syndrome, and Crohn's disease.

4. The use according to claim 2, wherein the condition is Alzheimer's disease.

5. The use according to claim 2, wherein the condition is major depressive disorder.

6. The use according to claim 2, wherein the condition is treatment-resistant depression.

7. The use according to claim 2, wherein the condition is anxious depression.

8. The use according to claim 2, wherein the condition is bipolar disorder.

9. The use according to claim 2, wherein the condition is anxiety.

10. The use according to claim 2, wherein the condition is epileptic seizures.

11. The use according to any one of claims 2-10, wherein the medicament is formulated for oral administration.

12. The pharmaceutical composition according to claim 1, wherein the compound is (*R**)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone.

13. The pharmaceutical composition according to claim 1, wherein the compound is (S*)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone.

14. The pharmaceutical composition according claim 1, wherein the compound is (*R**)-(2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(1H-pyrazol-5-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone.

15. The pharmaceutical composition according to claim 1, wherein the compound is (6S)-1-(5-Fluoropyrimidin-2-yl)-5-{[2-fluoro-3-(trifluoromethyl)phenyl]carbonyl}-6-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine.

16. The use according to any one of claims 2-11, wherein the compound is *(R*)*-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone.

17. The use according to any one of claims 2-11, wherein the compound is (S*)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone.

18. The use according to any one of claims 2-11, wherein the compound is *(R*)*-(2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(1H-pyrazol-5-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone.

19. The use according to any one of claims 2-11, wherein the compound is (6S)-1-(5-Fluoropyrimidin-2-yl)-5-{[2-fluoro-3-(trifluoromethyl)phenyl]carbonyl}-6-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine.

20. The pharmaceutical composition according to claim 1, for use in therapy.